施维雅营收达69亿欧元 肿瘤业务成增长主引擎

Group 1: Company Performance - The company reported a consolidated sales revenue of €6.9 billion for the fiscal year 2024-2025, representing a year-on-year growth of 16.2%, exceeding the target of €6 billion [1] - EBITDA increased by 47.2% to €1.9 billion, with a profit margin rising to 28.2% [1] - The oncology segment drove the growth, with revenues increasing by 54.6% to €2.21 billion, accounting for 32.2% of total revenue [1] Group 2: Oncology Business Highlights - The oncology drug Voranigo® has been a key driver of growth, with sales in the U.S. market increasing by 70.3%, contributing nearly 22% to the company's total revenue [1] - Voranigo® is approved in approximately 45 countries for treating a rare brain tumor, benefiting over 5,500 patients globally through early access programs [1] - The company is strengthening its oncology pipeline through collaborations, including agreements with Black Diamond Therapeutics and IDEAYA Biosciences [1] Group 3: Market Trends and Projections - According to IQVIA, global spending on oncology drugs is projected to reach $252 billion in 2024, with 74% concentrated in major developed markets [2] - U.S. oncology drug spending is expected to grow from $116 billion in 2024 to approximately $195 billion by 2029, with an annual growth rate of about 9.5% to 12.5% [2] - Emerging pharmaceutical markets are anticipated to see accelerated growth in oncology drug spending, with an average annual growth rate of 13.5% to 16.5% over the next five years [2] Group 4: Future Focus Areas - The company is expanding into neuroscience, focusing on treatment for refractory epilepsy and rare movement disorders, with 8 research-stage and 3 development-stage projects [3] - The company has established Servier Ventures to invest in biotech startups, enhancing its position in the biotech ecosystem [3] - Despite rapid growth in oncology, the cardiovascular and metabolic diseases segment remains a traditional strength, contributing 43.3% of revenue with a 1.8% year-on-year sales increase [3]